Travere Therapeutics Inc (NASDAQ:TVTX) price on Thursday, July 03, rose 1.15% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $15.01.
A look at the stock’s price movement, the close in the last trading session was $14.84, moving within a range at $14.84 and $15.09. The beta value (5-Year monthly) was 0.741. Turning to its 52-week performance, $25.29 and $7.72 were the 52-week high and 52-week low respectively. Overall, TVTX moved -2.53% over the past month.
Travere Therapeutics Inc’s market cap currently stands at around $1.33 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-01.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TVTX is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 8 recommend TVTX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TVTX’s current price about 1.60% and -11.01% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.68, while 7-day volatility ratio is 3.74% and 4.59% in the 30-day chart. Further, Travere Therapeutics Inc (TVTX) has a beta value of 0.75. Analysts have given the company’s stock an average 52-week price target of $21.5, forecast between a low of $12 and high of $33. Looking at the price targets, the low is 20.05% off current price level while to achieve the yearly target high, price needs to move -119.85%. Nonetheless, investors will most likely welcome a -43.24% jump to $21.5 which is the analysts’ median price.
If we refocus on Travere Therapeutics Inc (NASDAQ:TVTX), historical trading data shows that trading volumes averaged 1.4 over the past 10 days and 1.77 million over the past 3 months. The company’s latest data on shares outstanding shows there are 88.79 million shares.
The 1.47% of Travere Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 112.72% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 10.33 million on 2025-06-13, giving us a short ratio of 5.57. The data shows that as of 2025-06-13 short interest in Travere Therapeutics Inc (TVTX) stood at 1171.0 of shares outstanding, with shares short falling to 10.43 million registered in 2025-05-15. Current price change has pushed the stock 81.28% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TVTX stock continues to rise going into the next quarter.
